Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology · Hepatocellular Carcinoma

Deciphering Your Liver Imaging and Pathology Reports

At a Glance

Understanding your liver cancer imaging and pathology reports is crucial for your care. A LI-RADS 5 imaging score confidently identifies hepatocellular carcinoma in high-risk patients, while a pathology report details key risk markers like differentiation and microvascular invasion.

Medical reports can be intimidating, but they are the most important tools for your care team. Understanding the technical language in your imaging (CT/MRI) and pathology (tissue analysis) reports empowers you to ask the right questions and ensure your treatment plan is based on complete information.

Decoding Your Imaging Report (LI-RADS)

For patients at risk for liver cancer, doctors use a system called LI-RADS (Liver Imaging Reporting and Data System) to standardize how they describe liver masses [1][2].

The LI-RADS 5 Criteria

A “LI-RADS 5” (LR-5) score is highly specific, meaning the radiologist is definitely sure the mass is HCC [3][4]. In many cases, an LR-5 score allows you to begin treatment without a biopsy [5].

Important Note: The LI-RADS system is strictly designed and validated only for high-risk patients—meaning those who already have diagnosed cirrhosis or chronic Hepatitis B [6]. If applied to a patient without these specific conditions, it can lead to a false positive.

To reach an LR-5, the scan must show specific features:

  • APHE (Arterial Phase Hyperenhancement): The tumor “lights up” brightly when contrast dye is injected into the arteries [1][7].
  • Washout: The tumor then looks darker than the surrounding liver tissue in the later “portal venous” phase as the dye leaves the tumor [1][8].
  • Enhancing Capsule: A bright ring or “capsule” appears around the tumor in later stages of the scan [1].
  • Threshold Growth: If the tumor was seen on a previous scan and has grown significantly (e.g., 50% or more in 6 months), this is a major indicator [1].

Key Pathology Terms to Know

If you have surgery or a biopsy, a pathologist will examine the tissue. These terms predict how the cancer might behave in the future:

  • Differentiation: This describes how much the cancer cells look like healthy liver cells. Well-differentiated cells look more like normal liver and are typically less aggressive [9]. Poorly differentiated cells look very abnormal and tend to grow faster [10][11].
  • Microvascular Invasion (MVI): This means tiny clumps of cancer cells were found inside the small blood vessels near the tumor [12]. It is a key risk factor for the cancer coming back after surgery [13][14].
  • Satellite Nodules: These are small “islands” of cancer found near the main tumor. Their presence often signals a higher risk of recurrence [15][16].
  • Surgical Margins: This tells you if the surgeon was able to remove a “rim” of healthy tissue around the tumor. “Negative” or “Clear” margins mean no cancer cells were found at the edge of the removed tissue [17].

Pathology Report Completeness Checklist

According to international standards, a complete pathology report after surgery should include specific data points [17][18]. Use this checklist to ensure your report is thorough:

  1. [ ] Tumor Size: The maximum diameter of the largest tumor.
  2. [ ] Tumor Number: The total number of tumors found.
  3. [ ] Histological Grade: (Well, moderately, or poorly differentiated).
  4. [ ] Vascular Invasion: Explicitly stating if MVI is present or absent [12].
  5. [ ] Satellite Nodules: Whether additional small nodules were found [15].
  6. [ ] Margin Status: The distance (in millimeters) from the tumor to the edge of the removed tissue [17].
  7. [ ] Underlying Liver Status: A description of the “non-cancerous” liver tissue (e.g., presence of cirrhosis or inflammation) [17].

If any of these items are missing, it is appropriate to ask your doctor if an “addendum” (an updated note) can be requested from the pathologist to provide the missing information.

Common questions in this guide

What does a LI-RADS 5 score mean on my liver scan?
A LI-RADS 5 score means the radiologist is highly confident that the liver mass is hepatocellular carcinoma. For high-risk patients with underlying conditions like cirrhosis or Hepatitis B, this score often allows doctors to proceed directly to treatment without requiring a biopsy.
What is microvascular invasion (MVI)?
Microvascular invasion means that tiny clusters of cancer cells were found inside the small blood vessels near the main tumor. This is an important warning sign because it indicates a higher risk of the liver cancer returning after surgery.
What does differentiation mean on my pathology report?
Differentiation describes how much the cancer cells resemble healthy liver cells under a microscope. Well-differentiated tumors look more like normal tissue and are generally less aggressive, whereas poorly differentiated cells look very abnormal and tend to grow faster.
Why are clear surgical margins important?
Clear or negative surgical margins mean the surgeon successfully removed a rim of healthy tissue surrounding the tumor. When no cancer cells are found at the very edge of the removed tissue, it reduces the risk that cancer was left behind.
What are satellite nodules in liver cancer?
Satellite nodules are small islands of cancer found near the main tumor. Their presence is a sign that the cancer may be more aggressive, which often signals a higher risk of the cancer coming back in the future.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.My report mentions LI-RADS 5. Does this mean we can proceed with treatment without needing a biopsy?
  2. 2.The pathology report notes 'Microvascular Invasion' (MVI). How does this affect the risk of the cancer returning, and does it change our plan for follow-up?
  3. 3.What was the 'differentiation' of my tumor—well, moderately, or poorly differentiated?
  4. 4.Can you confirm if any 'satellite nodules' or 'microvascular invasion' were found beyond the main tumor?
  5. 5.Looking at the 'Completeness Checklist,' I don't see a mention of the status of my non-cancerous liver tissue. Is that information available?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.

    Santillan C, Fowler K, Kono Y, Chernyak V

    Abdominal radiology (New York) 2018; (43(1)):75-81 doi:10.1007/s00261-017-1291-4.

    PMID: 28828680
  2. 2

    Hepatocellular Carcinoma in Evolution: Correlation with CEUS LI-RADS.

    Nguyen SA, Merrill CD, Burrowes DP, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(4)):1028-1042 doi:10.1148/rg.210149.

    PMID: 35486579
  3. 3

    MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis.

    Shin J, Lee S, Hwang JA, et al.

    European radiology 2022; (32(5)):3319-3326 doi:10.1007/s00330-021-08382-y.

    PMID: 35031839
  4. 4

    CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.

    Lee S, Kim YY, Shin J, et al.

    Journal of the American College of Radiology : JACR 2020; (17(10)):1199-1206 doi:10.1016/j.jacr.2020.06.005.

    PMID: 32640250
  5. 5

    Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update.

    Kim TH, Kim SY, Tang A, Lee JM

    Clinical and molecular hepatology 2019; (25(3)):245-263 doi:10.3350/cmh.2018.0090.

    PMID: 30759967
  6. 6

    Liver Imaging Reporting and Data System criteria for the diagnosis of hepatocellular carcinoma in clinical practice: A pictorial minireview.

    Liava C, Sinakos E, Papadopoulou E, et al.

    World journal of gastroenterology 2022; (28(32)):4540-4556 doi:10.3748/wjg.v28.i32.4540.

    PMID: 36157932
  7. 7

    What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?

    Ghadimi M, Birnbaum J, Kamel IR, et al.

    European radiology 2022; (32(5)):3327-3333 doi:10.1007/s00330-021-08389-5.

    PMID: 34807269
  8. 8

    CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.

    van der Pol CB, McInnes MDF, Salameh JP, et al.

    Radiology 2022; (302(2)):326-335 doi:10.1148/radiol.2021211244.

    PMID: 34783596
  9. 9

    Molecular and histological correlations in liver cancer.

    Calderaro J, Ziol M, Paradis V, Zucman-Rossi J

    Journal of hepatology 2019; (71(3)):616-630 doi:10.1016/j.jhep.2019.06.001.

    PMID: 31195064
  10. 10

    Diagnostic accuracy of quantitative diffusion parameters in the pathological grading of hepatocellular carcinoma: A meta-analysis.

    Yang D, She H, Wang X, et al.

    Journal of magnetic resonance imaging : JMRI 2020; (51(5)):1581-1593 doi:10.1002/jmri.26963.

    PMID: 31654537
  11. 11

    A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.

    Wang Y, Yang L, Chen T, et al.

    Molecular cancer 2019; (18(1)):28 doi:10.1186/s12943-019-0957-7.

    PMID: 30782188
  12. 12

    Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma.

    Zhang Y, Lv X, Qiu J, et al.

    Journal of magnetic resonance imaging : JMRI 2021; (54(1)):134-143 doi:10.1002/jmri.27538.

    PMID: 33559293
  13. 13

    Systemic analysis identifying PVT1/DUSP13 axis for microvascular invasion in hepatocellular carcinoma.

    Su R, Zhang H, Zhang L, et al.

    Cancer medicine 2023; (12(7)):8937-8955 doi:10.1002/cam4.5546.

    PMID: 36524545
  14. 14

    Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis.

    Chen ZH, Zhang XP, Wang H, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2019; (21(8)):935-944 doi:10.1016/j.hpb.2019.02.003.

    PMID: 30871805
  15. 15

    Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion.

    Zhang K, Tao C, Wu F, et al.

    International journal of general medicine 2021; (14()):2259-2274 doi:10.2147/IJGM.S303896.

    PMID: 34113155
  16. 16

    Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy.

    Lu Z, Ni H, Yang X, et al.

    BMC cancer 2023; (23(1)):1150 doi:10.1186/s12885-023-11629-0.

    PMID: 38012581
  17. 17

    Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

    Burt AD, Alves V, Bedossa P, et al.

    Histopathology 2018; (73(3)):369-385 doi:10.1111/his.13520.

    PMID: 29573451
  18. 18

    The current landscape of therapies for hepatocellular carcinoma.

    Coffman-D'Annibale K, Xie C, Hrones DM, et al.

    Carcinogenesis 2023; (44(7)):537-548 doi:10.1093/carcin/bgad052.

    PMID: 37428789

This page explains liver cancer imaging and pathology terminology for educational purposes only. Always consult your oncologist or hepatologist to interpret your specific reports and medical results.

Get notified when new evidence is published on Adult hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.